[Show abstract] [Hide abstract]
ABSTRACT: Sixteen patients with relapsed mantle-cell lymphoma (MCL) were treated with the combination of fludarabine and cyclophosphamide (FC) with or without rituximab. All patients had received prior CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) chemotherapy, with a response rate of 63.5% (25% complete response), and a median duration of response of 10 months (range 1-32 months). Subsequent treatment with FC +/- rituximab produced a response rate of 75% with a higher complete response rate (56% P = 0.07 vs. CHOP), and a median duration of response of 11 months (4-25+ months). This study demonstrates that FC is a highly active regimen in patients relapsing following CHOP chemotherapy.
Leukemia and Lymphoma 05/2005; 46(4):549-52. DOI:10.1080/10428190400029841 · 2.89 Impact Factor